420 related articles for article (PubMed ID: 34104220)
1. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies.
Iaffaldano P; Lucisano G; Caputo F; Paolicelli D; Patti F; Zaffaroni M; Brescia Morra V; Pozzilli C; De Luca G; Inglese M; Salemi G; Maniscalco GT; Cocco E; Sola P; Lus G; Conte A; Amato MP; Granella F; Gasperini C; Bellantonio P; Totaro R; Rovaris M; Salvetti M; Torri Clerici VLA; Bergamaschi R; Maimone D; Scarpini E; Capobianco M; Comi G; Filippi M; Trojano M;
Ther Adv Neurol Disord; 2021; 14():17562864211019574. PubMed ID: 34104220
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Harding K; Williams O; Willis M; Hrastelj J; Rimmer A; Joseph F; Tomassini V; Wardle M; Pickersgill T; Robertson N; Tallantyre E
JAMA Neurol; 2019 May; 76(5):536-541. PubMed ID: 30776055
[TBL] [Abstract][Full Text] [Related]
3. Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
Guger M; Enzinger C; Leutmezer F; Di Pauli F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2024 Jun; 271(6):3142-3152. PubMed ID: 38430270
[TBL] [Abstract][Full Text] [Related]
4. Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
Hänninen K; Viitala M; Atula S; Laakso SM; Kuusisto H; Soilu-Hänninen M
J Neurol; 2022 Feb; 269(2):913-922. PubMed ID: 34170403
[TBL] [Abstract][Full Text] [Related]
5. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
7. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
9. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
11. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T;
Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
13. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
JAMA Neurol; 2021 Oct; 78(10):1197-1204. PubMed ID: 34398221
[TBL] [Abstract][Full Text] [Related]
14. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
15. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
16. Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis.
Pipek LZ; Mahler JV; Nascimento RFV; Apóstolos-Pereira SL; Silva GD; Callegaro D
Mult Scler Relat Disord; 2023 Mar; 71():104581. PubMed ID: 36848839
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
